Pfizer completed its $67 billion acquisition of Wyeth Pharmaceuticals last fall, just one in a string of recent mergers and acquisitions in the pharma industry. When asked how the two meetings departments would be affected and how procurement and sourcing would be handled, Joan Campion, a spokeswoman for Pfizer, declined to get specific: “I can tell you that Pfizer is continuing to evaluate its global workforce, which includes our medical meetings group, to determine how best to support
Register to view the full article
Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.
0 comments
Hide comments